Improvement in prosocial functioning after a switch to ziprasidone treatment

CNS Spectrums

Volumn 9, Issue 5, 2004, Pages 357-363

  Loebel, Antony ^a   Siu, Cynthia ^b   Romano, Steven ^c  

^a PFIZER INC   (United States)

^b Roche Laboratories   (United Kingdom)

^c Pfizer Inc ^*

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPARKINSON AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE; ZIPRASIDONE;

ADULT; ALERTNESS; ANXIETY; ATTENTION; CLINICAL FEATURE; COGNITIVE DEFECT; CONFERENCE PAPER; DEPRESSION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; LEARNING; MAJOR CLINICAL STUDY; MALE; MEMORY; PRIORITY JOURNAL; SCHIZOPHRENIA; SOCIAL INTERACTION;

EID: 2442487662     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1092852900009342     Document Type: Conference Paper

References (34)

1. Heinrichs DW, Hallon TE, Carpenter WT Jr. The quality of life scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr Bull. 1984;10:388-398.
2. Hegarty, JD, Baldessarini, RJ, Tohen, M. One hundred years of schizophrenia: a meta-analysis of the outcome literature. Am J Psychiatry. 1994;151:1409-1416.
3. Dickerson FB, Ringel, N, Parents F. Predictors of residential independence among outpatients with schizophrenia. Psychiatr Serv. 1999;5:515-519.
4. Macdonald EM, Hayes RL, Baglioni AJ Jr. The quantity and quality of the social networks of young people with early psychosis compared with closely matched control. Schizophr Res. 2000;46:25-30.
5. Haukka J, Suvisaari J, Lonnqvist J. Fertility of patients with schizophrenia, their siblings, and the general population: a cohort study from 1950 to 1959 in Finland. Am J Psychiatry. 2003;160:460-463.
6. Findling RL, Jayathilake K, Meltzer HY. Pre-morbid associality in neuroleptic-resistant and neuroleptic-responsive schizophrenia. Psychol Med. 1996;26:1033-1041.
7. Done DJ, Crow TJ, Johnstone EC, Sacker A. Childhood antecedents of schizophrenia and affective illness: social adjustment at ages 7 and 11. BMJ. 1994;309:699-703.
8. Mueser KT, Penn DL, Blanchard JJ, et al. Affect recognition in schizophrenia: a synthesis of findings across studies. J Abnorm Psychol. 1996;105:271-275.
9. Kring AT, Neale JM. Do schizophrenia patients show a disjunctive relationship between expressive, experiential, and psychophysiological components of emotion? J Abnorm Psychol. 1996;105:249-257.
10. Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry. 1996;153:321-330.
11. Green MF, Kern RS, Braff D, Mintz J. Neurocognition and functional outcome in schizophrenia: are we measuring the "right stuff"? Schizophr Bull. 2000;26:119-136.
12. Harvey PD, Keefe RS. Interpreting studies of cognitive change in schizophrenia with novel antipsychotic treatment. Am J Psychiatry. 2001;158:176-184.
13. Leucht S, Pitschel-Walz G, Engel RR, Kissling W. Amisulpride an unusual "atypical" antipsychotic: a meta-analysis of randomized controlled trials. Am J Psychiatry. 2002;159:180-190.
14. Harvey PD, Moriarty, PJ, Serper MR, Schnur E, Lieber D. Practice-related improvement in information processing with novel antipsychotic treatment. Schizophr Res. 2000;46:139-148.
15. Harvey PD, Meltzer HY, Simpson GM, et al. Improvement in cognitive function following a switch to ziprasidone from conventional antipsychotics, olanzapine, or risperidone in outpatients with schizophrenia. Schizophr Res. 2004;66:101-114.
16. Kring AM, Alpert M, Neale JM, Harvey PD. A multimethod, multichannel assessment of affective flattening in schizophrenia. Psychiatry Res. 1994;54:211-222.
17. Siris SG, Harmon GK, Endicott J. Postpsychotic depressive symptoms in hospitalized schizophrenic patients. Arch Gen Psychiatry. 1981;28:1122-1123.
18. Addington DD, Azorin JM, Falloon IR, Gerlach J, Hirsch SR, Siris SG. Clinical issues related to depression in schizophrenia: an international survey of psychiatrists. Acta Psychiatr Scand. 2002;105:189-195.
19. Meltzer HY, Alphs L, Green AI, et al. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry. 2003;60:82-91.
20. Weiden PJ, Simpson GM, Potkin SG, O'Sullivan RL. Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia. J Clin Psychiatry. 2003;64;580-588.
21. Weiden PJ, Daniel DG, Simpsom G, Romano SJ. Improvement in indices of health status in outpatients with schizophrenia switched to ziprasidone. J Clin Psychopharmacol. 2003;23:595-600.
22. Kay SR. Positive and Negative Syndromes in Schizophrenia. New York, NY: Brunner/Mazel; 1991.
23. Jastak, S. The Wide-Range Achievement Test-Revised. Wilmington, DE: Jastak Associates; 1984.
24. Spreen O, Strauss E. A Compendium of Neuropsychological Tests and Norms. 2nd ed. New York, NY: Oxford University Press; 1998.
25. Meltzer HY, McGurk SR. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull. 1999;25:233-255.
26. Cornblatt BA, Lenzenweger MF, Erlenmeyer-Kimling L. The continuous performance test, identical pairs version: II. Contrasting attentional profiles in schizophrenic and depressed patients. Psychiatry Res. 1989;29:65-85.
27. Oltmanns TF, Neale JM. Schizophrenic performance when distractors are present: attentional deficit or differential task difficulty? J Abnorm Psychol. 1975;84:205-209.
28. Heaton RK, Chelune CJ, Talley JL, Kay GG, Curtiss G. Wisconsin Card Sorting Test Manual-Revised and Expanded. Odessa, FL: Psychological Assessment Resources; 1993.
29. Lindenmeyer JP, Bernstein-Hyman R, Grochowski S. A new five-factor model of schizophrenia. Psychiatric Q. 1994;299-322.
30. Purnine DM, Carey KB, Maistro SM, Karey MP. Assessing positive and negative symptoms in patients with schizophrenia and mood disorders. J Nerv Ment Dis. 2000;188:653-661.
31. Buchanan RW, Holstein C, Breier A. The comparative efficacy and long-term effect of clozapine treatment on neuropsychological test performance. Biol Psychiatry. 1994;36:717-725.
32. Harvey PD, Serper MR, White L, et al. The convergence of neuropsychological testing and clinical ratings of cognitive impairment in patients with schizophrenia. Compr Psychiatry. 2001;42:306-313
33. Axelsson R, Lagerkvist-Briggs M. Factors predicting suicide in psychotic patients. Eur Arch Psychiatry Clin Neurosci. 1992;241:259-266.
34. Keck PE Jr, Reeves KR, Harrigan EP. Ziprasidone in the short-term treatment of patients with schizoaffective disorder: results from two double-blind place-controlled Multicenter studies. J Clin Psychopharmacol. 2001;21:27-35.